GSK submits Tyverb®/Tykerb® for first-line treatment of metastatic breast cancer in Europe, US
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has announced the submission of two simultaneous regulatory applications to expand the use of Tyverb®/Tykerb® (lapatinib). If authorised, lapatinib could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States.
Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix®
- Details
- Category: Pfizer
Pfizer Inc announced the results of a study that found that 47 percent of smokers with a history of cardiovascular disease who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with just 13.9 percent of those given placebo. These findings were presented today at the American College of Cardiology 58th Annual Scientific Session in Orlando, Fla.
Bayer Crop Science and the French research organization CNRS intensify collaboration
- Details
- Category: Bayer
Bayer CropScience and the National Centre for Scientific Research (Centre National de la Recherche Scientifique, CNRS) in Paris, France, have renewed a framework agreement signed in 2005. The new, joint research projects pursued under this agreement are intended to contribute to ensuring a sustainable food supply for a growing world population in the context of climate change.
Novartis makes an open offer to increase stake in Novartis India Ltd.
- Details
- Category: Novartis
Novartis has announced a tender offer to acquire an additional stake of up to approximately 39% in its majority-owned Indian subsidiary, Novartis India Ltd., from public shareholders at a price of Rs 351 per share.
HemCon Medical Technologies, Inc. Announces Improved Results from Live Nail Infection Study
- Details
- Category: Clinical Trials
HemCon has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary Mycosinate™ platform technology.
EMERFLU®, pandemic influenza vaccine for humans, approved in Australia
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that its pandemic influenza vaccine for human use Emerflu®, has been granted marketing authorization from the Australian Therapeutic Goods Administration (TGA). Emerflu® vaccine is now approved for the prevention of pandemic
influenza in Australia upon official declaration of a pandemic.
Glivec® recommended for use in Europe as first post-surgery treatment for GIST
- Details
- Category: Novartis
Novartis has received a positive opinion supporting European Union (EU) approval of Glivec® (imatinib)* as a post-surgery treatment for patients at significant risk of relapse following removal of gastrointestinal stromal tumors (GIST). The Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Glivec based on positive findings from a pivotal Phase III study, which showed that use of Glivec after surgery reduces risk of recurrence by approximately 89%[1].
More Pharma News ...
- New image of therapy for erectile difficulties
- Merck KGaA and Fast Forward, LLC Announce Collaboration
- U.S. Patent & Trademark Office Grants Reissue Patent Relating to Lipitor
- Roche acquires innovatis AG to complement its product portfolio
- The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
- Sanofi-aventis invests â¬100 million in new facility in Mexico
- Roche Annual General Meeting: dividend raised by 9 percent